Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New appointment at Topica Pharmaceuticals

This article was originally published in Scrip

Executive Summary

The privately held US biotechnology company Topica Pharmaceuticals has appointed Mark Davis vice-president of clinical development. He will lead the company's clinical development activities for its lead product candidate, luliconazole, for the treatment of onychomycosis (nail and nail bed fungal infections) and tinea pedis (athlete's foot). Topica expects to initiate a Phase I/IIa trial of luliconazole in the US for onychomycosis during the first quarter and to advance luliconazole into a Phase III clinical development programme for tinea pedis this year. Mr Davis has more than 27 years' experience in the biotech, pharmaceutical and medical device industries, having previously served in project leadership roles and as head of Clinical Operations at Onyx Pharmaceuticals, developing oncology products. Before that, he was senior director of clinical operations at Connetics, where he led clinical programmes for three dermatologic product approvals in the US.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts